Efficacy of [<sup>18</sup>F]PSMA-1007 PET/CT in Primary Staging of Prostate Carcinoma: A Systematic Review and Metaanalysis.
meta_analysis · Level I
Where this comes from
- Record sourced from PubMed, PMID 41130789.
- Also identified by DOI 10.2967/jnumed.125.269818 and PMC identifier 12766884.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Staging of prostate carcinoma (PCa) still largely relies on histopathologic examination of prostate tissue. In the last few years, PET/CT with radiotracers that target the prostate-specific membrane antigen (PSMA) has emerged as a noninvasive and sensitive method for staging of PCa. Compared with [<sup>68</sup>Ga]PSMA-11, [<sup>18</sup>F]PSMA-1007 is a relatively new radiotracer for PSMA PET/CT with favorable characteristics such as a longer physical half-life, reduced bladder background uptake, and improved availability due to production off-site. The objective of this systematic review and metaanalysis is to summarize the efficacy of [<sup>18</sup>F]PSMA-1007 in primary T, N, and M staging of PCa in comparison to histopathology. <b>Methods:</b> Clinical trials on primary staging of PCa with [<sup>18</sup>F]PSMA-1007 (both prospective and retrospective studies) were identified by a systematic search in PubMed. Relevant literature used histopathology as a comparator and reported discrete values for sensitivity and specificity. A metaanalysis assessed differences in diagnostic parameters. <b>Results:</b> Nineteen studies were included in this review: 10 studies reported on T staging (739 patients), 8 studies reported on N staging (865 patients), and 1 study reported on M staging (79 patients). For T staging, our metaanalyses of extraprostatic extension on a patient level based on 3 studies revealed a pooled sensitivity of 54% (95% CI, 46%-63%) and a pooled specificity of 92% (95% CI, 76%-98%). For N staging, our metaanalyses on detection of lymph node metastases on a patient level based on 5 studies revealed a pooled sensitivity of 42% (95% CI, 28%-57%) and a pooled specificity of 94% (95% CI, 90%-97%). In terms of sensitivity for M staging on a patient level, [<sup>18</sup>F]PSMA-1007 PET/CT outperformed all other tested conventional imaging modalities. <b>Conclusion:</b> PET/CT imaging with [<sup>18</sup>F]PSMA-1007 provides high sensitivity and specificity in T, N, and M staging of PCa when compared with histopathology. It offers the possibility to perform noninvasive primary T, N, and M staging before treatment in a single procedure.
Medical subject headings
- Prostatic Neoplasms
- Positron Emission Tomography Computed Tomography
- Oligopeptides
- Niacinamide
- Fluorine Radioisotopes